These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Phenytoin and fosphenytoin: a model of cost and clinical outcomes. Armstrong EP; Sauer KA; Downey MJ Pharmacotherapy; 1999 Jul; 19(7):844-53. PubMed ID: 10417033 [TBL] [Abstract][Full Text] [Related]
5. Recognizing and managing purple glove syndrome. Snelson C; Dieckman B Crit Care Nurse; 2000 Jun; 20(3):54-61. PubMed ID: 11876214 [No Abstract] [Full Text] [Related]
6. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Marchetti A; Magar R; Fischer J; Sloan E; Fischer P Clin Ther; 1996; 18(5):953-66. PubMed ID: 8930434 [TBL] [Abstract][Full Text] [Related]
7. Problem of managing patients with epilepsy in developing countries. Kuruvilla A Epilepsia; 1999 Oct; 40(10):1465-6. PubMed ID: 10528947 [No Abstract] [Full Text] [Related]
8. Inappropriate fosphenytoin use in the ED. Johnson J; Wrenn K Am J Emerg Med; 2001 Jul; 19(4):293-4. PubMed ID: 11447516 [TBL] [Abstract][Full Text] [Related]
9. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Sherry JH; Bechtel T Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16118859 [No Abstract] [Full Text] [Related]